Pharmacyclics (PCYC) Initiates Ibrutinib Combo Phase Ib/II in NSCLC (AZN)
Tweet Send to a Friend
Pharmacyclics (NASDAQ: PCYC) announced the initiation of PCYC-1135-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA) in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE